Related Experiment Video
Updated: May 12, 2026
Assessing Stem Cell DNA Integrity for Cardiac Cell Therapy
Published on: January 25, 2019
Evaluation of gene and cell-based therapies for cardiac regeneration
Mihai Bogdan Preda1, Guro Valen
1Institute of Cellular Biology and Pathology Nicolae Simionescu of the Romanian Academy, Bucharest, Romania.
Insights
New gene and cell therapies show promise for treating heart failure after myocardial infarction, but challenges remain in optimizing treatment for widespread use.
Area of Science:
- Cardiovascular Medicine
- Regenerative Medicine
- Biotechnology
Background:
- Acute myocardial infarction survivors face risks of heart failure due to cardiomyocyte loss and scar formation.
- Current treatments for severe heart failure, like heart transplantation, are limited by donor organ availability.
- Regenerating infarcted myocardium remains a challenge for existing pharmacological and interventional approaches.
Purpose of the Study:
- To review key findings from randomized clinical trials on gene and cell-based therapies for cardiovascular medicine.
- To highlight critical questions for future research in regenerative medicine for heart conditions.
Main Methods:
- Review of larger, randomized clinical trials in cardiovascular medicine.
- Focus on gene- and cell-based therapeutic approaches.
- Analysis of clinical experience to identify remaining challenges.
Main Results:
- Clinical trials have demonstrated the safety and feasibility of gene and cell-based therapies.
- Significant challenges persist in large-scale implementation of these novel treatments.
- Optimal cell/gene types, delivery routes, and DNA delivery systems require further investigation.
Conclusions:
- Gene and cell-based therapies offer promising avenues for regenerative medicine in treating heart conditions.
- Further research is essential to overcome current challenges and advance these therapies.
- Understanding therapeutic mechanisms is crucial for designing future clinical studies.
Abstract:
Although the treatment of acute myocardial infarction has improved considerably and the mortality rate is reduced, patients who survive may develop loss of cardiomyocytes, scar formation, ventricular remodeling, and ultimately heart failure. The treatment of the most severe types of heart failure is heart transplantation, but this therapeutic intervention is not available for a large number of patients due to a shortage of donor hearts. Since current pharmacological and interventional approaches are unsuccessful to regenerate infarcted myocardium, new approaches like gene- or cell-based therapies are tested to prevent loss of cardiac tissue, enhance angiogenesis, and to reduce left ventricular remodeling. Exciting and promising data on laboratory animals have moved the field rapidly into clinical trials. Although several clinical trials proved the safety and feasibility of using gene- and cell-based therapies, many challenges remain before large-scale novel treatment modules will be available. The purpose of this review is to summarize the key findings of larger, randomized clinical trials in cardiovascular medicine using both gene and cell-based therapy, and to emphasize the most significant questions that emerged from the clinical experience so far, such as the optimal gene or cell type to be used, the ideal delivery route, and for DNA the ideal delivery system. Understanding the mechanisms of gene- and cell-based therapies is essential for designing the next phase clinical studies in the field of regenerative medicine.
